Indeed, the introduction of targeted therapy for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) mutations increased the importance of discriminating AdC from SCC, since those mutations are highly associated with the former [9]. This evidence concerns the gene ROS1 and AIDS dementia complex.